Patient derived xenograft models 

What is it?

Patient derived xenograft (PDX) models are established by transplanting patient tumour cells directly into mice to generate highly relevant and predictive models for clinical translation. Kinn Therapeutics has special expertise in providing orthotopic PDX models (O-PDX), whereby human tumour tissue is engrafted to the anatomically relevant tissue in the recipient mouse. See here for more details.

Key benefits?

• PDX models reflect heterogeneous patient populations

• Stronger predictive power for clinical translation 

• O-PDX better captures tumour biology and microenvironment 

• O-PDX systems are well suited to model metastatic progression

Platform provides:

Kinn Therapeutics offers a diverse library of well characterised PDX models across an array of cancer types. PDX studies can also be designed to include standard-of-care therapies for comparison to novel agents to aid clinical development. Furthermore, combining PDX models with Kinn Therapeutics imaging technologies and bioassays enables drug developers to produce striking functional data with reliable quantitative analysis.